44,786 Shares in Evolus, Inc. (NASDAQ:EOLS) Bought by Semanteon Capital Management LP

Semanteon Capital Management LP bought a new position in Evolus, Inc. (NASDAQ:EOLS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 44,786 shares of the company’s stock, valued at approximately $472,000. Semanteon Capital Management LP owned 0.08% of Evolus at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Stonepine Capital Management LLC boosted its stake in Evolus by 14.9% in the 3rd quarter. Stonepine Capital Management LLC now owns 5,179,004 shares of the company’s stock worth $47,336,000 after purchasing an additional 672,807 shares during the period. Vanguard Group Inc. boosted its stake in Evolus by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,698,647 shares of the company’s stock worth $24,666,000 after purchasing an additional 741,451 shares during the period. Schroder Investment Management Group boosted its stake in Evolus by 7.1% in the 3rd quarter. Schroder Investment Management Group now owns 1,752,595 shares of the company’s stock worth $16,019,000 after purchasing an additional 115,647 shares during the period. Rice Hall James & Associates LLC boosted its stake in Evolus by 61.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 1,105,159 shares of the company’s stock worth $10,101,000 after purchasing an additional 421,890 shares during the period. Finally, AWH Capital L.P. boosted its stake in Evolus by 1.3% in the 3rd quarter. AWH Capital L.P. now owns 827,500 shares of the company’s stock worth $7,563,000 after purchasing an additional 11,000 shares during the period. 90.69% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently commented on EOLS shares. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, April 10th. Barclays upgraded shares of Evolus from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $10.00 to $16.00 in a research note on Monday, January 29th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Friday, March 1st.

Evolus Stock Down 0.3 %

Shares of EOLS stock traded down $0.03 on Friday, reaching $11.43. The stock had a trading volume of 248,985 shares, compared to its average volume of 610,462. The firm’s 50-day moving average is $13.43 and its two-hundred day moving average is $11.24. The firm has a market capitalization of $662.25 million, a price-to-earnings ratio of -10.49 and a beta of 1.45. Evolus, Inc. has a 12 month low of $7.07 and a 12 month high of $15.43.

Evolus (NASDAQ:EOLS) last issued its earnings results on Thursday, March 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). The firm had revenue of $61.00 million for the quarter, compared to the consensus estimate of $61.14 million. On average, sell-side analysts forecast that Evolus, Inc. will post -0.51 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Karah Herdman Parschauer sold 11,931 shares of the company’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $13.14, for a total value of $156,773.34. Following the sale, the director now directly owns 31,243 shares of the company’s stock, valued at approximately $410,533.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Evolus news, Director Karah Herdman Parschauer sold 11,931 shares of the stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $13.14, for a total value of $156,773.34. Following the transaction, the director now directly owns 31,243 shares of the company’s stock, valued at approximately $410,533.02. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 5,672 shares of the stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $13.92, for a total transaction of $78,954.24. Following the completion of the transaction, the chief financial officer now directly owns 154,201 shares in the company, valued at $2,146,477.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,969 shares of company stock valued at $831,005. 5.40% of the stock is owned by company insiders.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.